ADC Therapeutics shares preliminary 2025 revenue and cash data

ADC Therapeutics SA reported that it has released preliminary estimates for its revenue for the quarter and year ended December 31, 2025, along with preliminary cash and cash equivalents as of that date.

Accepted by SEC EDGAR 01/08/2026 - 05:04 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

ADC Therapeutics SA reported that it has released preliminary estimates for its revenue for the quarter and year ended December 31, 2025, along with preliminary cash and cash equivalents as of that date. These figures were disclosed in a press release dated January 8, 2026, which is attached as an exhibit.

The company emphasized that these revenue and cash numbers are preliminary, unaudited and based on management’s complex judgments and estimates. Actual results for the quarter and full year 2025 are not yet finalized or reviewed by independent auditors and may differ materially from these early estimates. The information is being furnished for disclosure purposes and is not deemed filed under the securities laws unless specifically incorporated by reference.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ADC Therapeutics SA (ADCT) disclose in this 8-K?

ADC Therapeutics SA disclosed that it issued a press release providing preliminary estimates of its revenue for the quarter and year ended December 31, 2025, and its preliminary cash and cash equivalents as of that date.

Are ADC Therapeutics SA’s 2025 figures in this 8-K audited?

No. The revenue and cash and cash equivalents figures are described as preliminary and unaudited, reflecting estimated financial results that may change once fully finalized and reviewed.

Which periods do ADC Therapeutics SA’s preliminary revenue estimates cover?

The preliminary revenue estimates cover the quarter ended December 31, 2025 and the full year ended December 31, 2025.

What financial position information did ADC Therapeutics SA provide?

The company provided a preliminary estimate of its cash and cash equivalents as of December 31, 2025, noting that this figure is based on management’s estimates and is unaudited.

How reliable are the preliminary financial results disclosed by ADC Therapeutics SA?

The company cautions that the preliminary financial information is not a comprehensive statement of results, has not been finalized or audited, and that subsequent information or events may lead to material differences from the final reported numbers.

Is the ADC Therapeutics SA press release in this 8-K considered filed with the SEC?

The company states that the information in the relevant items and the attached press release is furnished, not filed, and is not subject to Section 18 liabilities or incorporated into other filings unless specifically referenced.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false000177191000017719102026-01-082026-01-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 8, 2026

ADC Therapeutics SA

(Exact Name of Registrant as Specified in Its Charter)

Switzerland (State or Other Jurisdiction of Incorporation)			001-39071 (Commission File Number)						N/A (IRS Employer Identification Number)
Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of Principal Executive Offices) (Zip Code)						+41 21 653 02 00 (Registrant’s Telephone Number)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of Each Class			Trading Symbol			Name of Each Exchange on Which Registered
Common Shares, par value CHF 0.08 per share			ADCT			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 C.F.R. §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 C.F.R. §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

Item 7.01. Regulation FD Disclosure.

On January 8, 2026, ADC Therapeutics SA (the “Company”) issued a press release that includes preliminary revenue estimates for the quarter and year ended December 31, 2025, and the preliminary cash and cash equivalents as of December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

The revenue and cash and cash equivalents figures are preliminary and unaudited and reflect the Company’s estimated financial results. In preparing this information, management made a number of complex and subjective judgments and estimates about the appropriateness of certain reported amounts and disclosures. The Company’s actual financial results for the quarter and year ended December 31, 2025 have not yet been finalized by management or audited or reviewed by the Company’s independent auditors. The preliminary financial information is not a comprehensive statement of all financial results for the quarter or year ended December 31, 2025. Subsequent information or events may lead to material differences between the foregoing preliminary financial results and those reported in the Company’s subsequent SEC filings. Accordingly, investors should not place undue reliance on these preliminary financial results.

The information contained in these Items and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number			Description
99.1			Press Release dated January 08, 2025
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ADC Therapeutics SA
Date: January 08, 2025
			By:			/s/ Peter J. Graham
			Name:			Peter J. Graham
			Title:			Chief Legal Officer